Which varieties will be transferred to the new round of basic drug catalogue adjustments

Medical Network News, March 5th, a
new round of basic medicine catalog adjustment, came the
basic medicine catalog, to be adjusted.

On March 1, the National Health Commission held a 2021 national drug administration video and telephone conference
.
It is understood that the meeting has clarified the seven key points of this year's pharmaceutical policy work, namely, essential drugs, stable supply and price protection, centralized procurement of drugs, use monitoring, comprehensive clinical evaluation, pharmaceutical services, and policy research
.
In terms of key work on essential medicines, it includes: prioritizing the allocation and use of essential medicines; strengthening the evaluation and publicity of the essential medicine system; and optimizing and adjusting the national essential medicine list
.
As a matter of fact, as early as the end of last year, news of the adjustment of the basic medicine catalog was spread from time to time
.
In October last year, relevant state departments have organized a symposium on the basic medicine system, organizing relevant companies to participate in the meeting and discussing basic medicine policy issues
.
The main purpose of the meeting is to understand the implementation of the national essential medicine system in various regions and units, and solicit suggestions for the revision of the "National Essential Drug List Adjustment and Management Measures (Trial)"
.
In November last year, a discussion meeting for soliciting opinions on the National Essential Drug List Management Measures was held.
The meeting invited relevant authorities from 16 provinces.
The main content was to discuss work related to the revision of the Essential Drug List Management Measures
.
It is reported that the meeting predicted five key considerations for the adjustment of basic medicines in 2021: 1.
Drugs for infectious diseases; 2.
Drugs for chronic diseases, cancer, and tumors that turn chronic diseases; 3.
Drugs for common diseases; 4.
Diseases The leading direction is that if there is no medicine available for patients and symptomatic treatment is required, the most appropriate range should be selected; 5.
The product value mainly depends on the improvement of clinical endpoint indicators, which can improve the patient’s long-term quality of life and treat it as a cure.
Standard
.
Currently, the list of essential drugs being implemented in my country is the 2018 version of the 685 list
.
When the catalog was officially released, the National Health Commission emphasized the need to improve the catalog adjustment management mechanism, conduct regular evaluations of the catalog, and implement dynamic adjustments.
The adjustment cycle is in principle no more than 3 years; the newly approved and listed drugs are more effective than those already on the market.
For improved and reasonably priced drugs, the transfer procedure can be initiated in due course
.
This year is the third year of the publication of this edition of the basic medicine catalog.
According to the principle that the adjustment of the basic medicine catalog will not exceed 3 years, the adjustment of the basic medicine catalog will most likely start this year
.

　　Which varieties will be transferred to
today (March 4), the fourth session of the 13th National Committee of the Chinese People's Political Consultative Conference opens, officially kicking off the two sessions in 2021
.
At the two sessions every year, issues related to drug protection in primary medical institutions and the list of essential drugs are hot topics discussed by representatives and committee members
.
At the “Voice·Responsibility” medical and health sector National People’s Congress and CPPCC members’ symposium held today, some people’s congress representatives from medical institutions suggested that the current medical equipment used in primary medical institutions has not yet fully met the needs of primary care.
Some varieties Still in absence
.
Among the recommendations of the pharmaceutical industry collected at the above-mentioned symposium, some industry associations reported that the number of children suffering from diseases currently accounts for nearly 20% of the total number of patients.
Among conventional drugs , compared with more than 3,600 prescription drugs for adults, there are only more than 60 special drugs for children.
Kind
.
More than 95% of the medicines do not have safe packaging for children's medicines and are not equipped with special measuring devices
.
Part of the drug demand is met by halving the non-children's specific drugs, which has disadvantages such as inaccurate dosage and inaccurate efficacy
.
The new round of basic drug catalogue adjustments should focus on pediatric drugs and exclusive dosage forms for children's drugs
.
As we all know, the focus of the basic medicine and the medical insurance catalog is different, but the basic medicine may make it possible to enter the medical insurance
.
In fact, except for a very small number of drugs, the basic drug list is almost a reduced version of the medical insurance list.

.
After the 2020 medical insurance catalogue is adjusted, only 3 of the 685 basic medicine catalogues are not included in medical insurance
.
Prior to this, the relevant person in charge of the National Medical Insurance Bureau also said that the dynamic adjustment mechanism of the medical insurance catalog is currently being improved, which will comprehensively consider the connection with essential medicines, and prioritize the treatment of essential medicines out of the catalog into the medical insurance catalog according to procedures
.
Therefore, due to the various links between the basic medicine catalog and the medical insurance catalog, the current round of adjustment of the basic medicine catalog has also received great attention from pharmaceutical companies
.
However, whether it is the medical insurance catalogue or the basic drug catalogue, the catalogue adjustment work mentioned that the clinical value will be considered comprehensively, which is inseparable from the consideration of pharmacoeconomics
.
The evaluation of pharmacoeconomics needs to fully consider the safety and effectiveness of the medication regimen, including adverse reactions , compliance, dosage forms and many other factors affecting it
.
Therefore, pharmacoeconomic evaluation is particularly important for pharmaceutical companies to enter the basic drug catalog and medical insurance catalog
.